MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Zevra Therapeutics Inc

Closed

11.97 -5.45

Overview

Share price change

24h

Current

Min

11.97

Max

12.77

Key metrics

By Trading Economics

Income

33M

-3.1M

Sales

8.4M

20M

Profit margin

-15.19

Employees

59

EBITDA

11M

-5.4M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+90.92% upside

Dividends

By Dow Jones

Next Earnings

12 Aug 2025

Market Stats

By TradingEconomics

Market Cap

274M

699M

Previous open

17.42

Previous close

11.97

Zevra Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

27 Feb 2025, 15:29 UTC

Acquisitions, Mergers, Takeovers

Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million

5 Aug 2024, 11:25 UTC

Major Market Movers

Zevra Shares Rally Premarket After FDA Panel Backs Arimoclomol

Peer Comparison

Price change

Zevra Therapeutics Inc Forecast

Price Target

By TipRanks

90.92% upside

12 Months Forecast

Average 24.17 USD  90.92%

High 29 USD

Low 19 USD

Based on 7 Wall Street analysts offering 12 month price targets forZevra Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$